Anocca
PrivateLast Round
Early Funding
Aug 18, 2025
Total Funding Raised
$82.65M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Anocca is a clinical-stage biopharmaceutical company that develops T-cell receptor-engineered T cell (TCR-T) therapies to treat solid tumours and other diseases. Founded in 2014, the company has a fully integrated platform that includes research and development, a custom software ecosystem (AnoccaOS), and in-house cGMP manufacturing facilities in Södertälje, Sweden. Anocca's proprietary technology aims to scale the development of TCR-T cell therapies, enabling the systematic creation of personalized treatments for broad patient populations. The company is advancing its pipeline, with its lead program, VIDAR-1, in early-stage clinical trials for pancreatic cancer. Anocca is privately held and has received significant venture capital funding from investors including Mellby Gård, AMF, and Ramsbury.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Anocca Comparables
Compare Anocca with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enara Bio | 83% | |
| ImmunoScape | 81% | |
| Affini-T Therapeutics | 79% |
Anocca Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 18, 2025 | ||||
| Growth Equity | May 31, 2023 |
Key People
Founding team and executive leadership
Anocca Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMF Tjänstepension | Growth Equity |
| Mellby Gård | Early Funding, Growth Equity |
| Ramsbury Invest | Growth Equity |
| Swedbank Robur | Growth Equity |
| Michano | Growth Equity |
| Nidoco | Growth Equity |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 1070% MoM, reaching 3.4K.
Recent news
Latest coverage and updates
- is_developingAug 25, 2026
Anocca AB is developing precision T-cell receptor-engineered T-cell therapies targeting difficult-to-treat cancers.
Anocca Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access